Rhythm Pharmaceuticals, Inc. RYTM Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s total liabilities?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported total liabilities of $204.7M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s total liabilities decreased by 8.5% year-over-year, from $223.6M to $204.7M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s total liabilities has grown at a 59.2% compound annual growth rate (CAGR), from $20.55M to $210.17M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.